PMID- 25585824
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20181202
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Feb
TI  - Peritoneal ultrafiltration in congestive heart failure-findings reported from its 
      application in clinical practice: a systematic review.
PG  - 29-38
LID - 10.1007/s40620-014-0166-9 [doi]
AB  - INTRODUCTION: Peritoneal ultrafiltration (PUF) is proposed in the long-term 
      treatment of congestive heart insufficiency. However, the data in literature 
      available at present do not allow for conclusive meta-analysis. 
      OBJECTIVE/MATERIALS AND METHODS: A systematic review of the literature 
      (MEDLINE-EMBASE, 01/01/2003-31/12/2013, studies with >/=4 patients, adults, 
      non-ESRD) to highlight which patients PUF has been used in, how and with what 
      results. RESULTS: Consideration was given to 14 papers for a total of 471 
      patients. (1) Characteristics of the patients. Average age 71.6 years; diabetes 
      mellitus (DM) 47%; New York Heart Association (NYHA) class III 38.9%-class IV 
      59.8%; ischemic cardiopathy 67.8%; mean LVEF 35%. (2) PUF modality. Only 
      continuous ambulatory peritoneal dialysis (CAPD) in ten studies, only APD in two 
      studies, both in two studies. Overall CAPD was used in 56.2% of the pts. A single 
      exchange of icodextrin was used to treat 51% of patients on CAPD. The volume of 
      ultrafiltration obtained varied between 390 and 1,180 ml/die. (3) Effects of PUF. 
      Significant improvement in NYHA class and reduction in hospitalizations. Survival 
      at 12 months varying between 47 and 95%. Mortality seems to be associated with 
      DM, higher basal glomerular filtration rate, less change in ejection fraction 
      after PUF and less use of ICOs. LIMITATION: The main limitation of the selected 
      studies, mostly retrospective and with a limited number of patients, remains the 
      lack of clarity and uniformity of the selection criteria used. For this reason 
      extrapolations about survival require extreme caution and are not currently 
      possible. CONCLUSIONS: PUF improves symptomatology and reduces hospitalizations.
FAU - Viglino, Giusto
AU  - Viglino G
AD  - Nefrologia, Dialisi e Nutrizione Clinica, Ospedale San Lazzaro, Via P. Belli 26, 
      Alba, CN, Italy.
FAU - Neri, Loris
AU  - Neri L
FAU - Feola, Mauro
AU  - Feola M
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20150114
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
SB  - IM
MH  - Heart Failure/complications/physiopathology/*therapy
MH  - Humans
MH  - Kidney Failure, Chronic/complications/physiopathology/therapy
MH  - Peritoneal Cavity
MH  - *Peritoneal Dialysis, Continuous Ambulatory/adverse effects
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Ultrafiltration/adverse effects
EDAT- 2015/01/15 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/01/15 06:00
PHST- 2014/07/28 00:00 [received]
PHST- 2014/12/05 00:00 [accepted]
PHST- 2015/01/15 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - 10.1007/s40620-014-0166-9 [doi]
PST - ppublish
SO  - J Nephrol. 2015 Feb;28(1):29-38. doi: 10.1007/s40620-014-0166-9. Epub 2015 Jan 
      14.